Review | Published:

Effect of inulin-type fructans on blood lipid profile and glucose level: a systematic review and meta-analysis of randomized controlled trials

European Journal of Clinical Nutrition volume 71, pages 920 (2017) | Download Citation

Abstract

Background/Objectives:

This systematic review and meta-analysis was performed to assess the effects of inulin-type fructans (ITF) on human blood lipids and glucose homeostasis associated with metabolic abnormalities, including dyslipidemia, overweight or obesity, and type-2 diabetes mellitus (T2DM).

Subjects/Methods:

The MEDLINE, EMBASE and Cochrane Library databases were systematically searched for randomized controlled trials (RCTs) before January 2016. Human trials that investigated the effects of ITF supplementation on the lipid profile, fasting glucose and insulin were included using Review Manager 5.3.

Results:

Twenty RCTs with 607 adult participants were included in this systematic review and meta-analysis. In the overall analysis, the supplementation of ITF reduced only the low density lipoprotein-cholesterol (LDL-c) (mean difference (MD): –0.15; 95% confidence interval (CI): –0.29, –0.02; P=0.03) without affecting the other endpoints. Within the T2DM subgroup analysis, ITF supplementation was positively associated with a decreased fasting insulin concentration (MD: –4.01; 95% CI: –5.92, –2.09; P<0.0001) and increased high density lipoprotein-cholesterol (HDL-c) (MD: 0.07; 95% CI: 0, 0.14; P=0.05). Moreover, a reduced fasting glucose tendency was identified only in the T2DM subgroup (MD: –0.42; 95% CI: –0.90, 0.06; P=0.09). There was a potential publication bias, and few trials were available for the T2DM subgroup analysis.

Conclusions:

In summary, the use of ITF may have benefits for LDL-c reduction across all study populations, whereas HDL-c improvement and glucose control were demonstrated only in the T2DM subgroup. Thus, additional, well-powered, long-term, randomized clinical trials are required for a definitive conclusion. Overall, ITF supplementation may provide a novel direction for improving the lipid profile and glucose metabolism.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , . Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995; 125: 1401–1412.

  2. 2.

    , , , , , et al. Prebiotic effects: metabolic and health benefits. Br J Nutr 2010; 104 (Suppl 2), S1–S63.

  3. 3.

    . Inulin-type prebiotics – a review: part 1. Altern Med Rev 2008; 13: 315–329.

  4. 4.

    , , , . Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 2011; 7: 639–646.

  5. 5.

    , , . Modulation of the gut microbiota by nutrients with prebiotic properties: consequences for host health in the context of obesity and metabolic syndrome. Microb Cell Fact 2011; 10 (Suppl 1), S10.

  6. 6.

    , , , , , . Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br J Nutr 2009; 101: 541–550.

  7. 7.

    , , , , , et al. Dietary intervention impact on gut microbial gene richness. Nature 2013; 500: 585–588.

  8. 8.

    , , , , , et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013; 500: 541–546.

  9. 9.

    , , , , , et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013; 498: 99–103.

  10. 10.

    , , , , , et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490: 55–60.

  11. 11.

    , , , , , et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57: 1470–1481.

  12. 12.

    , , , , , et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57–63.

  13. 13.

    , , , , , et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010; 5: e9085.

  14. 14.

    , , , , , et al. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480–484.

  15. 15.

    , , , , , . An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027–1031.

  16. 16.

    , . Gut microflora as a target for energy and metabolic homeostasis. Curr Opin Clin Nutr Metab Care 2007; 10: 729–734.

  17. 17.

    , , , , , et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 101: 15718–15723.

  18. 18.

    , , , , , . Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 1996; 38: 916–919.

  19. 19.

    , , . Can dietary fructans lower serum glucose? J Diabetes 2011; 3: 58–66.

  20. 20.

    , , , . Systematic review of the effects of inulin-type fructans on blood lipid profiles: a meta-analysis. Journal of Hygiene Research 2010; 39: 172–176.

  21. 21.

    , , , . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006–1012.

  22. 22.

    , . Cochrane handbook for systematic reviews of interventions. Cochrane collaboration 2011. Available at: .

  23. 23.

    , . Some statistical methods for combining experimental results. International J Technol Assess Health Care 1990; 6: 5–30.

  24. 24.

    , , , . Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.

  25. 25.

    , , , , , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343: d4002.

  26. 26.

    , , , . Inulin controls inflammation and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized-controlled clinical trial. Int J Food Sci and Nutr 2014; 65: 117–123.

  27. 27.

    , , . Effects of high performance inulin supplementation on glycemic status and lipid profile in women with type 2 diabetes: a randomized, placebo-controlled clinical trial. Health Promot Perspect 2013; 3: 55–63.

  28. 28.

    , , , . Effect of nondigestible oligosaccharides on large-bowel functions, blood lipid concentrations and glucose absorption in young healthy male subjects. Eur J Clin Nutr 1999; 53: 1–7.

  29. 29.

    , . Long-term administration of inulin-type fructans has no significant lipid-lowering effect in normolipidemic humans. Metabol – Clin and Experim 2007; 56: 1093–1098.

  30. 30.

    , , . Addition of inulin to a moderately high-carbohydrate diet reduces hepatic lipogenesis and plasma triacylglycerol concentrations in humans. American J Clin Nutr 2003; 77: 559–564.

  31. 31.

    , , , , , . Chronic consumption of short-chain fructooligosaccharides does not affect basal hepatic glucose production or insulin resistance in type 2 diabetics. J Nutr 2000; 130: 1572–1577.

  32. 32.

    , , . The effect of ingestion of inulin on blood lipids and gastrointestinal symptoms in healthy females. Br J Nutr 1997; 78: 215–222.

  33. 33.

    , , , , , et al. Inulin-enriched pasta affects lipid profile and Lp(a) concentrations in Italian young healthy male volunteers. Eur J Nutr 2008; 47: 453–459.

  34. 34.

    , , , . Freeze-dried powdered yacon: effects of FOS on serum glucose, lipids and intestinal transit in the elderly. Eur J Clin Nutr 2014; 53: 1457–1464.

  35. 35.

    , , . Effects of dietary inulin on serum lipids, blood glucose and the gastrointestinal environment in hypercholesterolemic men. Nutr Res 2000; 20: 191–201.

  36. 36.

    , . Effects of dietary inulin on serum lipids. J Nutr 1999; 129: 1474S–1477S.

  37. 37.

    , , , , , et al. Effects of short-chain fructo-oligosaccharides on glucose and lipid metabolism in mild hypercholesterolaemic individuals. Clin Nutr 2004; 23: 331–340.

  38. 38.

    , , , . The effect of the daily intake of inulin on fasting lipid, insulin and glucose concentrations in middle-aged men and women. Br J Nutr 1999; 82: 23–30.

  39. 39.

    , , , , , et al. The impact of oligofructose on stimulation of gut hormones, appetite regulation and adiposity. Obesity (Silver Spring) 2014; 22: 1430–1438.

  40. 40.

    , , , , , . Double blind randomized clinical trial controlled by placebo with a fos enriched cookie on saciety and cardiovascular risk factors in obese patients. Nutr Hosp 2013; 28: 78–85.

  41. 41.

    , , , , , et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 2013; 62: 1112–1121.

  42. 42.

    , , , , , et al. Yacon syrup: beneficial effects on obesity and insulin resistance in humans. Clin Nutr 2009; 28: 182–187.

  43. 43.

    , . Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr 2009; 89: 1751–1759.

  44. 44.

    , , , , , . The inclusion of a partial meal replacement with or without inulin to a calorie restricted diet contributes to reach recommended intakes of micronutrients and decrease plasma triglycerides: a randomized clinical trial in obese Mexican women. Nutr J 2012; 11: 44.

  45. 45.

    , , , , , . Consumption of fructooligosaccharides does not favorably affect blood glucose and serum lipid concentrations in patients with type 2 diabetes. Am J Clin Nuti 1999; 69: 64–69.

  46. 46.

    , , , , , et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol 2010; 61: 69–78.

  47. 47.

    , , , , , . A systematic review and meta-analysis of the prebiotics and synbiotics effects on glycaemia, insulin concentrations and lipid parameters in adult patients with overweight or obesity. Clin Nutr 2015; 34: 845–858.

  48. 48.

    . Dietary fructans and serum triacylglycerols: a meta-analysis of randomized controlled trials. J Nutr 2007; 137: 2552S–2556S.

  49. 49.

    , . Dietary fructans. Annu Rev Nutr 1998; 18: 117–143.

  50. 50.

    , , , , , et al. Prebiotic effects: metabolic and health benefits. Br J Nutr 2010; 104 (Suppl 2), S1–S63.

  51. 51.

    , , , , , et al. Nondigestible fructans alter gastrointestinal barrier function, gene expression, histomorphology, and the microbiota profiles of diet-induced obese C57BL/6 J mice. J Nutr 2016; 146: 949–956.

  52. 52.

    . An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990; 82: 1916–1924.

  53. 53.

    1996. National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand. N Z Med J 1996; 109: 224–231.

  54. 54.

    , , , , , et al. Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial. JAMA 2011; 306: 831–839.

  55. 55.

    , . Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings. Int J Mol Sci 2010; 11: 2499–2522.

  56. 56.

    , , . Dietary fibers affect viscosity of solutions and simulated human gastric and small intestinal digesta. J Nutr 2006; 136: 913–919.

  57. 57.

    , , . High propionic acid fermentations and mineral accumulation in the cecum of rats adapted to different levels of inulin. J Nutr 1991; 121: 1730–1737.

  58. 58.

    , , , , . Inulin and oligofructose modulate lipid metabolism in animals: review of biochemical events and future prospects. Br J Nutr 2002; 87 (Suppl 2), S255–S259.

  59. 59.

    , , , , . Effect of rectal infusion of short chain fatty acids in human subjects. Am J Gastroenterology 1989; 84: 1027–1033.

  60. 60.

    , , , , , et al. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci USA 2011; 108: 8030–8035.

  61. 61.

    , . Intestinal glucose metabolism revisited. Diabetes Res Clin Pract 2014; 105: 295–301.

  62. 62.

    , , , , , et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014; 156: 84–96.

  63. 63.

    , , , , , et al. Fermentation of fructooligosaccharides and inulin by bifidobacteria: a comparative study of pure and fecal cultures. Appl Environ Microbiol 2005; 71: 6150–6158.

  64. 64.

    , , . Dietary inulin lowers plasma cholesterol and triacylglycerol and alters biliary bile acid profile in hamsters. J Nutr 1998; 128: 1937–1943.

  65. 65.

    , , , , , et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292: E740–E747.

  66. 66.

    , , , , , et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761–1772.

  67. 67.

    , , , . Early differences in fecal microbiota composition in children may predict overweight. American J Clin Nutr 2008; 87: 534–538.

  68. 68.

    , , , , , et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 2010; 18: 190–195.

  69. 69.

    , , , , , et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007; 50: 2374–2383.

  70. 70.

    , , . A double-blind placebo-controlled study to establish the bifidogenic dose of inulin in healthy humans. European J Clin Nutr 2007; 61: 1189–1195.

  71. 71.

    , . The bifidogenic effect of inulin and oligofructose and its consequences for gut health. Eur J Clin Nutr 2009; 63: 1277–1289.

  72. 72.

    , , , , , . Involvement of endogenous glucagon-like peptide-1(7-36) amide on glycaemia-lowering effect of oligofructose in streptozotocin-treated rats. J Endocrinol 2005; 185: 457–465.

  73. 73.

    , , , , , . Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes 2006; 55: 1484–1490.

  74. 74.

    , , , , , et al. Relation between colonic proglucagon expression and metabolic response to oligofructose in high fat diet-fed mice. Life Sci 2006; 79: 1007–1013.

  75. 75.

    , , , , , . Physiological effects of dietary fructans extracted from Agave tequilana Gto. and Dasylirion spp. Br J Nutr 2008; 99: 254–261.

  76. 76.

    , , , . Impact of inulin and oligofructose on gastrointestinal peptides. Br J Nutr 2005; 93 (Suppl 1), S157–S161.

  77. 77.

    , . The fermentable fibre inulin increases postprandial serum short-chain fatty acids and reduces free-fatty acids and ghrelin in healthy subjects. Appl Physiol Nutr Metab 2010; 35: 9–16.

  78. 78.

    , , , , , et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 2012; 61: 364–371.

  79. 79.

    . The biology of incretin hormones. Cell Metab 2006; 3: 153–165.

Download references

Acknowledgements

This review was supported by the National Natural Science Foundation of China (NSFC313220143).

Author contributions

Feitong Liu and Hongwei Zhou designed the research; Feitong Liu, Prabhakar M and Jianqing Ju conducted the research; Feitong Liu and Haoyu Long conducted the quality assessment of the studies; Feitong Liu analysed the data and drafted the manuscript; and Feitong Liu and Prabhakar M finalized the manuscript. Feitong Liu had primary responsibility for the final content. All authors have read and approved the final manuscript.

Author information

Affiliations

  1. State Key Laboratory of Organ Failure Research, Department of Environmental Health, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, China

    • F Liu
    • , M Prabhakar
    • , H Long
    •  & H-W Zhou
  2. Shandong University of Traditional Chinese Medicine, Jinan, China

    • J Ju
  3. Division of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China

    • H-W Zhou

Authors

  1. Search for F Liu in:

  2. Search for M Prabhakar in:

  3. Search for J Ju in:

  4. Search for H Long in:

  5. Search for H-W Zhou in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to H-W Zhou.

Supplementary information

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/ejcn.2016.156

Supplementary Information accompanies this paper on European Journal of Clinical Nutrition website (http://www.nature.com/ejcn)

Further reading Further reading